Cooper Financial Group Makes New $373,000 Investment in Edwards Lifesciences Corporation $EW

Key Points

• Cooper Financial Group made a new investment of $373,000 in Edwards Lifesciences Corporation, acquiring 4,769 shares of the medical research company.
• Several hedge funds, including Arlington Trust Co LLC and Valeo Financial Advisors LLC, have also increased their stakes in Edwards Lifesciences, indicating growing institutional interest.
• Analysts have mixed ratings for Edwards Lifesciences, with JPMorgan Chase and Piper Sandler raising target prices while the company has a consensus rating of "Moderate Buy".

Cooper Financial Group bought a new position in Edwards Lifesciences Corporation (NYSE:EW - Free Report) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 4,769 shares of the medical research company's stock, valued at approximately $373,000.

A number of other hedge funds have also added to or reduced their stakes in the stock. Arlington Trust Co LLC grew its stake in Edwards Lifesciences by 1.2% in the 1st quarter. Arlington Trust Co LLC now owns 11,092 shares of the medical research company's stock worth $804,000 after acquiring an additional 135 shares in the last quarter. Valeo Financial Advisors LLC lifted its position in shares of Edwards Lifesciences by 2.8% in the 1st quarter. Valeo Financial Advisors LLC now owns 5,136 shares of the medical research company's stock worth $372,000 after purchasing an additional 142 shares during the period. Allspring Global Investments Holdings LLC lifted its position in shares of Edwards Lifesciences by 0.5% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company's stock worth $2,170,000 after purchasing an additional 145 shares during the period. Dakota Wealth Management lifted its position in shares of Edwards Lifesciences by 2.5% in the 2nd quarter. Dakota Wealth Management now owns 6,048 shares of the medical research company's stock worth $473,000 after purchasing an additional 146 shares during the period. Finally, Leo Wealth LLC lifted its position in shares of Edwards Lifesciences by 1.2% in the 1st quarter. Leo Wealth LLC now owns 12,488 shares of the medical research company's stock worth $905,000 after purchasing an additional 150 shares during the period. 79.46% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently commented on EW. Wall Street Zen cut shares of Edwards Lifesciences from a "strong-buy" rating to a "buy" rating in a research report on Monday. JPMorgan Chase & Co. increased their target price on shares of Edwards Lifesciences from $80.00 to $85.00 and gave the company a "neutral" rating in a research report on Friday, July 25th. Morgan Stanley increased their target price on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the company an "equal weight" rating in a research report on Tuesday, July 15th. Piper Sandler upped their price target on shares of Edwards Lifesciences from $83.00 to $90.00 and gave the company an "overweight" rating in a research note on Friday, July 25th. Finally, Royal Bank Of Canada upped their price target on shares of Edwards Lifesciences from $85.00 to $89.00 and gave the company an "outperform" rating in a research note on Friday, July 25th. Three analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $86.61.

Edwards Lifesciences Stock Up 0.5%

NYSE:EW opened at $76.66 on Friday. The firm has a market capitalization of $45.01 billion, a P/E ratio of 11.03, a PEG ratio of 3.67 and a beta of 1.05. Edwards Lifesciences Corporation has a 1-year low of $64.00 and a 1-year high of $83.00. The company's fifty day moving average price is $78.55 and its 200-day moving average price is $75.89. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, topping analysts' consensus estimates of $0.62 by $0.05. The firm had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The business's quarterly revenue was up 11.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.70 earnings per share. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. As a group, equities research analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Insiders Place Their Bets

In other news, insider Larry L. Wood sold 8,950 shares of the stock in a transaction on Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the sale, the insider owned 206,900 shares in the company, valued at $16,150,614. This represents a 4.15% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Daniel J. Lippis sold 4,114 shares of the stock in a transaction on Monday, July 28th. The stock was sold at an average price of $79.46, for a total transaction of $326,898.44. Following the completion of the sale, the vice president owned 22,002 shares in the company, valued at $1,748,278.92. The trade was a 15.75% decrease in their position. The disclosure for this sale can be found here. 1.29% of the stock is owned by corporate insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.